Valuation: Solid Biosciences Inc.

Market Cap 1.04B 896M 837M 767M 1.44B 99.82B 1.47B 9.87B 3.87B 50.06B 3.92B 3.84B 166B P/E 2026 *
-5.59x
P/E 2027 * -5.65x
Enterprise Value 750M 644M 601M 551M 1.04B 71.71B 1.05B 7.09B 2.78B 35.96B 2.82B 2.76B 119B EV / Sales 2026 *
-
EV / Sales 2027 * 71.3x
Free-Float
88.22%
Yield 2026 *
-
Yield 2027 * -
1 day+7.27%
1 week+7.45%
Current month+20.84%
1 month+11.70%
3 months+60.20%
6 months+65.65%
Current year+72.70%
1 week 8.73
Extreme 8.73
9.87
1 month 7.65
Extreme 7.65
9.87
Current year 4.92
Extreme 4.92
11.45
1 year 3.79
Extreme 3.79
11.45
3 years 1.81
Extreme 1.81
15.05
5 years 1.81
Extreme 1.81
51.3
10 years 1.81
Extreme 1.81
822.6
Manager TitleAgeSince
Corporate Officer/Principal - 2014-08-31
Chief Executive Officer 55 2022-12-01
Director of Finance/CFO 48 2023-01-08
Director TitleAgeSince
Director/Board Member 52 2013-02-28
Director/Board Member 60 2015-10-31
Director/Board Member 46 2015-10-31
Date Insider Type Main position Quantity % Market Cap.
7/2/26 Fiscal year

Chairman

6,880 0.0070%
6/10/26 Free

Founder

77,500 0.0787%
2/13/26 Fiscal year

Chief Operating Officer

36,843 0.0473%
Change 5-day change 1-year change 3-year change Capi.($)
+7.27%+7.45%+67.93%+159.04% 1.04B
-1.90%+3.12%+81.70%+110.88% 72.21B
+0.32%+16.70%+56.32%+93.03% 63.98B
+1.71%-1.22%+2.71%+501.29% 28.53B
+3.63%+8.57%+62.12%+24.72% 25.07B
+21.96%+21.98%+1.54%+2.50% 28.42B
+0.33%+6.77%+40.07%-13.35% 20.04B
0.00%-2.78%+247.46%+423.83% 18.19B
+1.81%+1.43%+23.67%+527.06% 15.96B
+2.39%+7.96%+44.96%+157.77% 13.48B
Average +3.75%+5.89%+62.85%+198.68% 28.69B
Weighted average by Cap. +2.52%+6.70%+61.14%+164.16%

Financials

2026 *2027 *
Net sales - 10.87M 9.32M 8.7M 7.99M 15.02M 1.04B 15.26M 103M 40.22M 521M 40.8M 39.92M 1.72B
Net income -224M -193M -180M -165M -310M -21.45B -315M -2.12B -831M -10.76B -843M -824M -35.57B -238M -204M -190M -175M -328M -22.71B -334M -2.25B -879M -11.39B -892M -873M -37.66B
Net Debt -294M -252M -236M -216M -407M -28.12B -413M -2.78B -1.09B -14.1B -1.1B -1.08B -46.62B -270M -231M -216M -198M -372M -25.76B -379M -2.55B -997M -12.92B -1.01B -990M -42.71B
Logo Solid Biosciences Inc.
Solid Biosciences Inc. is a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases. The Company is focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy and additional assets for the treatment of genetic cardiac and neuromuscular disease. It also has two cardiac pipeline gene transfer programs, SGT-401 for BAG3-mediated DCM, which is in early preclinical development, and SGT-701 for RBM20 DCM, which is in the discovery stage. In addition to its gene transfer candidates, the Company has development programs focusing on platform technologies, including capsid libraries and dual gene expression, a technology that allows it to package multiple transgenes into one capsid.
Employees
121
Date Price Change Volume
26-08-19 US$9.740 +7.27% 1,243,988
26-08-18 US$9.080 -0.22% 536,331
26-08-17 US$9.100 -1.09% 694,166
26-08-14 US$9.200 +1.32% 759,399
26-08-13 US$9.080 +0.17% 828,257
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
9.740USD
Average target price
17.64USD
Spread / Average Target
+81.07%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SLDB Stock